1766-P: VRB-103 Is a Potent, Orally Bioavailable Amylin Analog with a Strong Selectivity towards Human Amylin Receptors vs. Calcitonin Receptor
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1766-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von MARTIJN FENAUX und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Amylin is a peptide hormone secreted from pancreatic beta-cells that reduces appetite, delays gastric emptying, and decreases glucagon release. Amylin functions by activating human amylin receptors (hAMY1R, hAMY2R and hAMY3R), which consist of the calcitonin receptor (hCTR) in complex with receptor activity modifying proteins (RAMP1-3). Clinical stage amylin analogs, such as cagrilintide and eloralintide, have demonstrated distinct profiles for tolerability and body weight reduction with weekly subcutaneous administrations. Amylin analogs vary in their selectivity for hAMY1R-3R relative to hCTR, which may have implications for clinical efficacy and tolerability. VRB-103 is a novel amylin analog designed to be optimized for oral administration. Here we evaluated the in vitro potency of VRB-103 for activation of hAMY1R-3R and hCTR, and the relative selectivity on hAMY1R-3R vs hCTR.
Methods
VRB-103 was tested in CHO cell lines stably overexpressing hAMY1R, hAMY2R, hAMY3R, or hCTR. Eloralintide and cagrilintide were used as comparators.
Results
VRB-103 demonstrated potent in vitro activities against hAMY1R, hAMY2R and hAMY3R with EC50s of 0.057 nM, 0.146 nM, and 0.011 nM, respectively. VRB-103 showed lower activity against hCTR compared to the amylin receptors. When normalized to cagrilintide, this resulted in hAMY1R, hAMY1R, and hAMY3R selectivity relative to hCTR of 20.6, 5.5 and 4.4-fold, respectively. By comparison, eloralintide showed normalized relative lower selectivity for hAMY1R, hAMY2Rand hAMY3R activation versus hCTR of 5.0, 0.8 and 1.4-fold, respectively.
Conclusion
VRB-103 is a potent and orally bioavailable amylin analog with a strong selectivity towards human amylin receptors relative to hCTR. The amylin receptor selectivity of VRB-103 was more pronounced than that of the comparators analyzed. VRB-103 is currently in development as a once-weekly oral tablet for obesity. Disclosure M. Fenaux: None. C.L. Jones: Employee; Current; Verdiva Bio. W. Zhong: None. Y. Li: Employee; Current; Sciwind Biosciences. S. Hao: Employee; Current; Sciwind Biosciences. Z. Li: Employee; Current; Sciwind Biosciences. Y. Wang: Employee; Current; Sciwind Biosciences. J. Zhao: Employee; Current; Sciwind Biosciences. J. Francis: Employee; Current; Verdiva Bio. H. Zou: Employee; Current; Sciwind Biosciences. X. Wu: Employee; Current; Sciwind Biosciences. R. Zhu: Employee; Current; Sciwind Biosciences.
Zitieren
APA
FENAUX, M., JONES, C. L., ZHONG, W., LI, Y., HAO, S., LI, Z., WANG, Y., ZHAO, J., FRANCIS, J., ZOU, H., WU, X., & ZHU, R. (2026). 1766-P: VRB-103 Is a Potent, Orally Bioavailable Amylin Analog with a Strong Selectivity towards Human Amylin Receptors vs. Calcitonin Receptor. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1766-p
Vancouver
FENAUX M, JONES CL, ZHONG W, LI Y, HAO S, LI Z, et al. 1766-P: VRB-103 Is a Potent, Orally Bioavailable Amylin Analog with a Strong Selectivity towards Human Amylin Receptors vs. Calcitonin Receptor. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1766-p
BibTeX
@article{FENAUX2026,
author = {FENAUX, MARTIJN and JONES, CATHERINE L. and ZHONG, WEIDONG and LI, YAN and HAO, SUJUAN and LI, ZHAOYING and WANG, YAN and ZHAO, JINYI and FRANCIS, JAMES and ZOU, HAIXIA and WU, XINLE and ZHU, RUI},
title = {1766-P: VRB-103 Is a Potent, Orally Bioavailable Amylin Analog with a Strong Selectivity towards Human Amylin Receptors vs. Calcitonin Receptor},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1766-p}
}
EUVIMED